In parallel with robust efforts world-wide to develop effective neuroprotection for established disease, resources are being mobilized to delineate risk factors and implement preventive measures in a concerted effort to forestall the anticipated Alzheimer disease (AD) epidemic. A review of heritable and 'acquired' dementia risk factors, many operating at midlife, is presented in a companion paper. Objectives: In 2009, an Alzheimer Risk Assessment Clinic (ARAC) was established at the Jewish General Hospital (Montreal) to address the concerns increasingly being voiced by active middle-aged individuals at risk for AD. A positive family history of AD and/or perceived changes in personal cognitive function (predominantly short-term memory) are main reasons for referral. The primary objectives of ARAC are to (i) ascertain, inform and mitigate the risks of developing AD in cognitivelyhealthy persons aged 40-65 based on best available medical and epidemiological evidence, (ii) conduct scientific research on midlife dementia risk and prevention in this population and (iii) provide instruction in dementia risk assessment and management to health professionals, clinical/research fellows, medical residents and students. ARAC infrastructure, evaluation protocol, risk profile classification scheme, interventions, knowledge dissemination program, case vignettes, and seminal research projects are described. Conclusions: It is hoped that ARAC and similar initiatives will help prevent or delay dementia by innovating effective interventions based on increasingly nuanced estimation of modifiable AD risk in presymptomatic persons. Les principales raisons de consultation sont une histoire familiale positive de MA et/ou des changements perçus de la fonction cognitive personnelle (surtout la mémoire à court terme). Les objectifs primaires de la CERMA sont : 1) d'évaluer, d'informer et de diminuer les risques de présenter la MA chez des individus en bonne santé cognitive qui sont âgés de 40 à 65 ans, en se basant sur les meilleures données médicales et épidémiologiques disponibles ; 2) d'effectuer des recherches scientifiques sur le risque de démence au milieu de la vie et sur la prévention chez cette population et 3) de fournir de l'enseignement sur l'évaluation du risque de démence et sur sa prise en charge aux professionnels de la santé, aux collègues cliniciens ou chercheurs, aux résidents et aux étudiants. Nous décrivons l'infrastructure, le protocole d'évaluation, le plan de classification du profil de risque, les interventions, le programme de diffusion des connaissances, des descriptions de cas et les projets de recherche novateurs de la CERMA. Conclusions : Nous espérons que la CERMA et des initiatives similaires aideront à prévenir ou à retarder la démence au moyen d'interventions efficaces novatrices fondées sur une estimation de plus en plus nuancée des risques modifiables de la MA chez les individus présymptomatiques.
Introduction
Alzheimer disease (AD) is a dementing, neurodegenerative disorder that affects approximately 5-10% of North Americans over the age of 65 and 30-50% of those who reach 90. Many more individuals experience mild cognitive impairment (MCI), a frequent clinical precursor of AD characterized by cognitive dysfunction (usually involving short-term memory) that fails to meet dementia criteria. It has been estimated that persons with MCI convert to incipient AD at a rate of approximately 15% per year, although the speed of progression may vary substantially degenerative process. As described in a companion article 2 , various medical and psychosocial conditions, many operative at midlife, have emerged as potential risk or protective factors for the development of sporadic AD. Although several of these risk factors are heritable, others are determined by environment or lifestyle and may prove modifiable. Prominent among the latter are: cardiovascular risk factors (hypertension, dyslipidemia, diabetes -which may both exacerbate AD pathology and promote vascular dementia), impoverished mental stimulation, psychological distress (late-life depression, chronic anxiety), and sub-optimal nutrition ('Western' diet) [3] [4] [5] [6] [7] . This realization has generated considerable optimism that effective prevention or delay of the disease may soon be possible [8] [9] [10] .
A need to know
The oldest of the 'baby-boomer' generation (née 1946-1964) are now facing retirement and their apprehensions about cognitive deterioration and AD are increasingly being voiced. As we learn more about individual AD vulnerability profiles -and commensurate with growing general access to 'unfiltered' biomedical information -it is anticipated that an informed public will increasingly inquire about personal estimates of AD risk. Data garnered in the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study published in 2005 11 and 2009 12 have indicated end-user interest in dementia risk assessment, including predictive apolipoprotein E (APOE) genotyping, even in the perceived absence of effective disease pre-emption. Risk Evaluation and Education for Alzheimer's Disease was a randomized controlled trial designed to determine the impact of APOE genotype disclosure for AD risk assessment in adult children of individuals with autopsy-confirmed or clinically-diagnosed AD. The AD risk was ascertained in the control group solely on the basis of family history and gender. Reasons prompting first-degree relatives of AD subjects to seek personal dementia risk evaluations included opportunity to contribute to research (93.9%), arrangement of personal affairs (87.4%), expectation that effective treatments will be developed (86.8%), planning of long-term care (81.4%), preparation of family members for the possibility of illness (77.8%), expedition of future plans (75%), and relief accruing from low-risk assessment (69.6%) 13, 14 . Speaking to the safety of presymptomatic APOE testing, middle-aged children of AD parents who tested negative for the ε4 allele were relieved to learn of their status and ε4-positive individuals have thus far shown no stigmata of psychosocial harm after being informed that they were carriers of this risk allele 11 . Moreover, initial evidence suggests that knowledge of personal AD risk profiles may permit individuals to make insightful decisions regarding implementation of potential prevention strategies and spur healthy midlife adults to adopt or modify behaviours that might protect against future disease 11, 15 . The motivation to accept 'inconvenient' lifestyle modifications or potentially disagreeable medications may be contingent on the perceived magnitude of the AD risk 11 . Some may question the validity of presymptomatic AD risk assessment in the absence of level 1 evidence of effective therapeutic intervention. While the latter would certainly be welcome, this concern should be viewed in the context of the following considerations: (i) Patterson and colleagues 5 opined, correctly in our perspective, that "very few recommendations can be based on highest quality [level 1] evidence…[because it is] highly unlikely that randomized control trials will ever be conducted on many of the risk factors identified… [therefore] recommendations must necessarily be based on less stringent types of evidence". (ii) Action taken on 'best available', as distinguished from 'best possible', evidence may be warranted in so far as many of the interventions currently implicated in ameliorating AD risk entail lifestyle adjustments (e.g. dietary modifications, physical exercise, protective headgear) that, in contradistinction to pharmacotherapy, are more likely to prove 'inconvenient' than hazardous 10, 16 .
The Alzheimer Risk Assessment Clinic
Memory Clinics in North America are inundated with referrals for costly and labour-intensive assessments of cognitive decline in our rapidly-aging population and are ill-equipped to address concerns about future cognitive performance raised by healthy midlife persons (the "worried well") at risk for the disease. To meet the clinical needs and conduct essential research involving this midlife population, an Alzheimer Risk Assessment Clinic (ARAC) was established in September 2009 at the Jewish General Hospital (JGH) (McGill University) in Montreal, the first such facility in Canada to our knowledge. The launch of this initiative and its first two years of operation were enabled by generous funding from the Mary Katz Claman Foundation (MKCF), a local non-profit organization affiliated with the Alzheimer Groupe Inc., whose mission is to raise funds and awareness for AD support groups and research in Montreal (http://www.mkc-foundation.com).
Objectives
The primary objectives of ARAC are to (i) ascertain, inform and mitigate the risks of developing AD in cognitively-intact adults based on best available medical and epidemiological evidence, (ii) conduct scientific research which addresses these concerns in this population and (iii) provide instruction in dementia risk assessment and management to health professionals, clinical/research fellows, medical residents and students. This endeavour may be viewed in the larger context of 'midlife medicine', a relatively recent but burgeoning discipline with considerable clinical and research implications for neurological and 'geriatric' disease [17] [18] [19] .
Target population and conditions
The Alzheimer Risk Assessment Clinic was conceived in order to estimate personal dementia risk and provide recommendations for its mitigation in midlife men and women (age 40-65) of all ethnic groups and socioeconomic strata. We opted for an upper age cut-off for ARAC at 65 years as there already exists at our institution a well-established Memory Clinic within the Division of Geriatrics catering to the memory concerns of the elderly. It was felt that the availability of two clinics addressing memory in persons older than 65 at our institution would result in a needless and costly duplication of efforts (already severely strained) as many subjects would likely seek advise at both facilities. The bottom cut-off of 40 years was selected based on recent epidemiological evidence ascribing potentially-modifiable susceptibility factors at midlife for latelife dementia and AD 2 and a paucity of information about modifiable AD risk at earlier stages of the life cycle. This policy would warrant re-visiting in the event that modifiable AD risk factors determined to be operational prior to midlife become apparent.
Based on earlier experience at the JGH Memory Clinic and private practice (family medicine, neurology, geriatrics, psychiatry), it was anticipated and confirmed that the majority of individuals seeking assessment at ARAC would represent three main categories of concern: 1) Persons with a family history (parents, siblings, etc.) of AD or other dementia, 2) persons suspecting deterioration of their memory or other cognitive functions, and 3) individuals with known or suspected AD risk factors which are potentially modifiable (e.g. dyslipidemia, diabetes, hypertension). These categories are not mutually exclusive and ARAC patients often manifest various combinations of these factors.
ARAC infrastructure and personnel
The JGH is a 637-bed McGill University teaching hospital and a national leader in the fields of geriatric medicine and aging-related neurodegenerative diseases. It houses the JGH Memory Clinic, an established tertiary care facility for the evaluation of memory loss in Montreal and environs, and the Lady Davis Institute which hosts about a dozen laboratories devoted to basic and clinical research in AD and related disorders. The Alzheimer Risk Assessment Clinic consists of a reception area and two examination rooms within the hospital's Department of Neurology.
A qualified and enthusiastic team has been assembled to direct and implement ARAC activities at the JGH. The following is a census of the personnel and their primary responsibilities:
• Director: The director designs and oversees ARAC clinical and research activities and performs (or reviews) medical, neuropsychosocial and nutritional client 'intakes', renders diagnostic formulations and proposes interventions (lab tests, referrals, etc.), as detailed in the ARAC Workbook (Appendix 1).
• Research Coordinator: Organizes all aspects of research conducted at ARAC including liaising with JGH Research Ethics Office, recruitment of study volunteers, protocol execution, data entry and analysis, genotyping and public relations.
• Receptionist: Responsible for appointments, referrals, test bookings, correspondence.
• Nurse: Intake of patient demographics, education, occupation, socioeconomic status, vital signs, head circumference [20] [21] [22] ; blood draws.
• Nutritionist (offsite): ARAC patients with perceived vulnerability in the domain of Nutrition (see below) are referred to a nutritionist at the hospital's Cardiovascular Prevention Centre. The latter obtains a detailed dietary history, including antioxidant/nutraceutical exposure, and makes dietary recommendations.
• Neuropsychologists (two; offsite): In addition to use of standard neuropsychological instruments, novel measurement tools were developed to focus specifically on cognitive and neuropsychiatric profiles germane to the midlife ARAC population (see below). Referred patients receive counseling for enhanced cognitive engagement and/or stress management and neuropsychological data are generated for research projects.
• To fulfill its teaching mandate (see Objectives), ARAC welcomes students, residents and fellows to participate in all aspects of its activities (clinical and research) on a rotating basis. In the first half-year of operation, a neuroscience undergraduate student assisted in the development of the ARAC Workbook, a midlife dementia risk questionnaire and in-house genotyping for apolipoprotein E and BDNF polymorphisms. The ARAC experience may be particularly attractive to trainees in neurology, neuropsychology, geriatrics, psychiatry and family medicine.
ARAC 'flow diagram'
The following is a bulleted description of the ARAC referral process, sequence of assessments, diagnostic formulation and plan. An ARAC Workbook containing all components of the evaluation is presented as Appendix 1.
• Referral: Individual aged 40-65 with concerns about personal prospects of cognitive decline and dementia is referred to ARAC from a physician's office (generalist or specialist) or a Memory Clinic.
• Nursing Intake: An ARAC nurse interviews/examines the patient and records the following data in a structured and personalized ARAC workbook: (i) demographics, (ii) education, (iii) occupation, (iv) socioeconomic status, (v) vital signs, (vi) height, weight and body-mass index (BMI), and (vii) head circumference.
• Medical Intake: Medical doctors, nurse or trainee obtains or performs (i) family history, (ii) medical history, (iii) surgical history, (iv) list of medications/nutraceuticals, (v) smoking/alcohol history, (vi) leisure physical activity scale, (vii) current laboratory data, (viii) neuropsychosocial screen (neuropsychiatric history, leisure cognitive activity scale, personality scale, Montreal Cognitive Assessment (MoCA) score, social network scale), and (ix) nutritional screen.
• Diagnostic Formulation: On the basis of the above information, the clinic director assigns a Midlife Dementia Risk Score (modified after 7 ) and ascertains the subject's Dementia Risk Profile: P0=no discernible risk; P1=Genetic risk (positive family history, apolipoprotein E ε4 allele when available); P2=Metabolic risk (hypertension, diabetes, metabolic syndrome, low exercise, dyslipidemia, prior stroke, possibly sleep apnea); P3=Nutritional risk (low Mediterranean-style diet score); P4=Cognitive risk (low education, low cognitive engagement, head injury); and P5=Psychological risk (chronic anxiety, laterlife depression, impoverished social network). Individuals may harbour risk in no (P0), one or more profile categories (P1-P5).
• Interventions: (i) Unless current laboratory data are available, venous blood is drawn on all subjects for determination of complete blood count (CBC), HgbA1C, electrolytes, glucose, BUN/Cr, liver functions, albumin, lipid profile, thyroid stimulating hormone (TSH), folate, B 12 , homocysteine, α-tocopherol and C-reactive protein. ) is arranged for P1 subjects with strong family histories of early-onset (< age 60 years) dementia. (x) P1-P5 patients are generally given annual followup appointments in ARAC to re-evaluate ongoing dementia risk and monitor compliance with potential risk-lowering recommendations. Longitudinal follow-up of pre-symptomatic patients with well-defined AD risk factors (including repeated blood-work and, for research subjects, neuroimaging-see below) should provide valuable prospective data concerning the natural history of the disease. (xi) ARAC does not assume the responsibilities for primary medical and psychiatric care of its clientele. For example, if depression is suspected or documented by ARAC personnel and/or affiliated neuropsychologist, consultation with colleagues in the Dept. of Psychiatry is arranged. We do not initiate antidepressant (or for that matter, antihypertensive, antidiabetic or lipid-lowering) therapy in ARAC as such intervention and its monitoring are beyond the mandate, expertise and resources of the clinic and remain the responsibility of the referring physician, the Dept. of Psychiatry, or our institute's Cardiovascular Prevention Centre. Along similar lines, patients are referred to the JGH Memory Clinic for definitive investigation and management of possible MCI/dementia when significant cognitive impairment is disclosed. By focusing exclusively on dementia risk assessment of a generally healthy and high-functioning population, ARAC is uniquely empowered to satisfy an unmet and growing clinical need with high-throughput and minimal overlap with preexisting medical services and resources.
• Correspondence: Following each ARAC visit, a letter is sent to the referring MD consisting of a brief case report, a summary of the dementia risk profile(s) delineated, an intervention plan, and several salient literature references on AD risk prevention (see Appendix 3, for sample case summaries).
• Effectiveness assessments: Effectiveness of the interventions will be monitored in two ways: 1) by adducing evidence of improvement in performance or compliance to recommendations over time (e.g annually) on quantitative measures sampled in the ARAC Workbook (vital signs/BMI/HgbA1C, leisure exercise and cognitive scores, Mediterranean diet scores, social network scores, etc.) and, for subjects with cognitive (P4) and psychological (P5) risk factors, formal neuropsychological scores, and 2) externally, in collaboration with Dr. S. Ahmed as described in Section 3.5 (iii).
ARAC research
There currently exists no method which unequivocally arrests, retards or reverses neuronal degeneration and progressive clinical decline in AD and related disorders. While efforts to develop effective neurotherapeutics continue apace, the research community has been galvanized to identify modifiable risk factors and investigate preventive strategies in an attempt to stem the forecasted AD epidemic 8, 10, 23 . Alzheimer Risk Assessment Clinic is poised to conduct fundamental and translational research along these lines in parallel with its aforementioned clinical activities. Ample opportunity exists for extensive collaboration between ARAC and the highly developed network of clinical facilities and basic laboratories devoted to aging and neurodegeneration at the JGH and affiliated Lady Davis Institute and McGill University. The following is a brief description of several lead projects currently ongoing or in advanced stages of planning at ARAC:
(i) ARAC Neuroimaging Initiative
While delineation of dementia risk profiles and risk reduction are the raison d'être of ARAC, observational and interventional studies based on dementia outcome per se would entail extensive and costly long-term follow-up periods (20-30 years) and would be exceedingly challenging to perform. In order to circumvent this limitation, the ARAC Neuroimaging Initiative strives to identify surrogate markers of subclinical ("intermediate") phenotypes associated with defined AD risk profiles (P1-P5, vide supra) which may prove useful for monitoring the efficacy of interventional strategies. In collaboration with Dr. A. Thiel (JGH Dept. of Neurology, McGill University), we are evaluating three imaging parameters in ARAC volunteers which are typically related to early neurodegeneration or compensatory plasticity in the normal elderly: (A) Surface cortical thickness (SCT) derived from T1-weighted MR images using a novel method developed in-house 24 , (B) positron emission tomography (PET) with the 18 F-labelled benzodiazepine receptor ligand, flumazenil and the new High Resolution Research Tomograph (HRRT) for measurement of in vivo neuronal density 24 , and (C) the PET ligand, 11 C-PIB (Pittsburgh-B-Compound), a marker of cerebral amyloid deposits. In addition to patients with MCI and AD, increased PIB binding has been reported in a proportion of normal elderly subjects possibly reflecting enhanced AD risk. At ARAC, these three imaging modalities are offered in the context of research to midlife subjects at high and low risk for AD representing the various genetic and 'acquired' dementia risk profiles (P1-P5) described above. Molecular testing for the APOE ε4 allele 10 and the BDNF Val66Met polymorphism 25 , genetic factors implicated in sporadic AD, is performed on peripheral venous blood leukocytes collected from subjects recruited for neuroimaging (and other consenting ARAC volunteers). We hypothesize that SCT and neuronal density will vary inversely, and PIB labeling will vary directly, with increasing genetic, metabolic, nutritional and/or neuropsychological vulnerability in middle-aged men and women.
(ii) ARAC Biospectroscopy Study
As alluded to in project (i), the advent of biological markers that correlate with AD risk profiles at midlife would represent a major breakthrough in the evaluation and management of this chronic neurodegenerative disorder. Biospectroscopy is an optical-based analytical technology that provides a simultaneous and integrated measure of all metabolic activities taking place in a biological sample or field and then uses the accruing spectral data to create a profile of molecular biomarkers. Biospectroscopic analyses in the near-infrared (NIRS) performed in collaboration with Dr. David Burns (McGill Dept. of Chemistry) and Molecular Biometrics Inc. (Norwood, MA) on small volumes of human plasma revealed metabolomic signatures that distinguished, with high sensitivity and specificity, early sporadic AD from normal elderly controls (NEC) and patients with idiopathic Parkinson disease (PD). The metabolomic profiles observed in AD plasma are consistent with altered oxidation states of protein and other blood-borne constituents 26, 27 . Importantly, persons with amnestic MCI exhibited a wide range of values on plasma NIRS, extensively overlapping those of both the AD and NEC cohorts. We conjectured that subjects with plasma NIR spectra in the "AD" range may be at higher risk for imminent deterioration to dementia than neuropsychologically-identical individuals whose spectral signatures fall within "normal" limits. We are set to determine in ARAC volunteers whether pathological NIRS spectra akin to those accruing to MCI/AD occur in midlife individuals at increased risk for AD (high midlife dementia risk scores; specific risk domains, P1-P5). We will ascertain whether the blood NIRS signatures are impacted by the presence or absence of APOE ε4 and BDNF Val66Met polymorphisms and whether pathological NIR spectra correlate with evidence of cortical thinning, neuronal loss and β-amyloid deposition on neuroimaging (SCT, 18 F-flumazenil, and 11C-PIB scanning, respectively) in this population.
(iii) External Evaluation of ARAC
In light of the increasing burden of chronic illness in Canada, new approaches are emerging to implement innovative models for chronic disease management and prevention. To this end, primary care settings are re-structuring many of their activities in line with key elements of the Chronic Care Model (CCM). The CCM is an evidence-based client-centered framework that defines the important elements and strategies needed to improve care for individuals with chronic disease 28 . As a new initiative, an external evaluation of ARAC's structure, accessibility, processes, deliverables, knowledge transfer and social impact is highly desirable as a means to ascertain the efficacy of the enterprise and guide it to a maximally successful outcome. In collaboration with Dr. S. Ahmed (McGill School of Physical & Occupational therapy), an external assessment of ARAC will be conducted using a program evaluation approach, PESTLE (Political, Economic, Social, Technological, and Legal evaluation) instruments and a Long Range Strategic Planning (LRSP) exercise 29 as part of a national effort to ascertain success factors and barriers to implementation of CCM interventions in Canada 30 .
ARAC Knowledge Dissemination Program
A guiding principle of the ARAC concept is the empowerment of citizens with the knowledge and resources to take matters of AD risk containment into their own hands 28 . To facilitate this process, multi-media outreach programs complement clinic activities by educating the community at large about key medical and lifestyle factors (diet, exercise, blood pressure control, cognitive engagement, etc.) currently implicated in the management of AD risk. To help raise this public awareness, patients attending ARAC receive a 20-page public brochure on AD risks and prevention adapted from a document on this topic provided by the National Institutes of Health, US. In addition, information is made available regarding community-based resources for physical fitness, cognitive engagement, and social stimulation in the greater Montreal area. Institutional and public lectures are presented by ARAC staff, and ARAC activities are disseminated campus-wide via hospital and university periodicals and professional publications. An interactive ARAC website and production of a video documentary on dementia prevention are also under consideration to promote the clinic's educational agenda.
CONCLUSIONS
The Alzheimer Risk Assessment Clinic's mandate is to provide clinical estimates of dementia risk and strategies for its control based on best available medical evidence to midlife individuals seeking such information. The data collected will serve two main purposes: (i) to inform individuals of their personal dementia risk profiles and offer recommendations for their mitigation where possible and (ii) to establish a prospective database on midlife AD risk factors in a large, ethnically-diverse population. The latter should constitute a valuable resource for research on the predispositions and prevention of AD and other aging-related dementias. It is envisioned that fundamental, translational and clinical research on this defined population will disclose important information concerning the amenability of risk behaviours and co-morbidities to modification, the natural history of cognitive decline as a function of specific midlife risk profiles (Genetic, Metabolic, Nutritional, Cognitive, Psychological) and their interplay, the delineation of surrogate biomarkers (neuroimaging, etc.) of current/future cognitive vulnerability and disease-preventing interventions, and feasibility of this model for the management of other chronic illnesses (e.g. Parkinson disease) in Canada and elsewhere.
With the recent launch of large-scale initiatives like "Prevent Alzheimer's Disease by 2020" in the US 8 , we may anticipate with confidence the rapid accrual of new data linking late-life dementia to potentially-modifiable risk profiles operative in the middle years. It is hoped that initiatives along the lines of ARAC will assist in forestalling the feared AD epidemic by innovating effective prevention based on increasingly nuanced estimation of personal AD risk in presymptomatic persons. The person is shown a matrix containing six simple geometric visual designed in a 2x3 matrix presented for 10 seconds each of the three times. After each exposure, the individual is asked to reproduce as many of the designs as possible, in the same location as they appear on the display. After a 25-minute delay the person is asked to reproduce the designs again followed by a recognition trial in which the individual is shown 12 designs one at a time. The subject is asked to respond "yes" to those designs that were included in the original matrix and "no" to distracters. The manual provides a scoring guide for each design according to drawing and spatial placement criteria and various numerical scores are obtained. Reliability coefficients range from .60 for trial 1 to .84 for trial 3. The reliability coefficient for the total recall is .80. The adult version is for individuals age 18 to 89. The CTT has two parts and is designed to minimize the influence of language so it could be used in cross-cultural settings. In Trial 1 the respondent is instructed to rapidly draw a line connecting the circles numbered 1 through 25 in consecutive order. Circles with odd numbers are pink and circles with even numbers are yellow. The incidental fact that color alternates with each succeeding number is not mentioned. For Trial 2 the examiner instructs the respondent to rapidly draw a line between numbered circles, maintaining the sequence of numbers, but alternating between pink and yellow colors. The time for the completion of each part 1 and 2 is recorded in seconds. In addition, this test includes a qualitative scoring of number of errors, nearmisses, and prompts; further, an "Interference Index" is calculated. Both Parts 1 and 2 require perceptual tracking of a sequence and speeded performance. However, Part 2 also requires divided attention. The Interference Index is an indicator of the need to elucidate the added task requirements of Part 2 and is thought to be a pure measure of the interference, attributable to the more complex divided attention and the alternating sequencing tasks in Part 2. Several CTT scores present problems for computing traditional correlation coefficients between the first and second testing. The ranges of the errors, prompts, near-misses, and interference index scores are restricted due to the infrequency with which normal subjects demonstrate these performance features. This artificially reduces the magnitude of the reliability coefficients; thus, it was decided that test-retest reliabilities will be considered only for CTT variable with sufficient range and distribution scores, such as completion time. 
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